Polymyxin B-Based Hemoperfusion for the Treatment of Endotoxic Shock

Guest Editors
Claudio Ronco, Vicenza
Antonio Artigas, Sabadell
Massimo Antonelli, Rome

4 figures, 1 in color, and 2 tables, 2014
Disclosure Statement Guest Editors
The guest editors declare that they have no financial conflict of interest.

This publication was supported by an unrestricted education grant from Toray Medical Co. Ltd., Estor S.p.A. and Ferrer Farma.
www.toray-medical.com/en/
www.estor.it
www.ferrerfarma.com
Contents

1 Preface
Ronco, C. (Vicenza); Artigas, A. (Sabadell); Antonelli, M. (Rome)

2 State of the Art in the Clinical Treatment of Endotoxic Shock
Artigas, A. (Sabadell); Piccinni, P. (Vicenza)

5 Endotoxin Removal: History of a Mission
Ronco, C. (Vicenza)

9 New Trends in Polymyxin B Hemoperfusion: From 2006 to 2013
Cruz, D.N. (San Diego, Calif.)

14 Endotoxin Removal: Bringing the Mission to North America
Foster, D.; Klein, D.I.; Guadagni, G.; Walker, P.M. (Toronto, Ont.)

18 Future Options for (Economically) Sustainable Research in Sepsis
Romay, E.; Ferrer, R. (Terrassa)

22 Polymyxin B Hemoperfusion in Clinical Practice: The Picture from an Unbound Collaborative Registry
The Early Use of Polymyxin B Hemoperfusion in the Abdominal Sepsis 2 (EUPHAS2) Collaborative Group

26 Author Index/Subject Index